FIELD: molecular biology, biotechnology, gene engineering, in particular diagnosis of atypical pneumonias.;SUBSTANCE: invention relates to DNA based on identified protein antigen epitope SARS-CoV. Particularly disclosed are nucleotide sequences of synthetic genes encoding recombinant protein fragments containing coronavirus protein antigen determinants SARS-CoV, represented in SEQ ID NO:1 - SEQ ID NO:8; as well as SARS-CoV virus protein fragments encoded by DNA sequences with amino acid sequences represented in SEQ ID NO:10 - SEQ ID NO:17. Said fragments are isolated by using preliminary obtained fusion protein by attachment to its N-terminal end GST-S-transferase protein with sequence represented in SEQ ID NO:9. Fusion proteins are useful in manufacturing of preparations for diagnosis of acute respiratory virus SARS-CoV.;EFFECT: new diagnostic agents for diagnosis of atypical pneumonias.;2 cl
展开▼
机译:技术领域:分子生物学,生物技术,基因工程,特别是非典型肺炎的诊断。发明领域:本发明涉及基于鉴定的蛋白抗原表位SARS-CoV的DNA。特别公开的是编码含有冠状病毒蛋白抗原决定簇SARS-CoV的重组蛋白片段的合成基因的核苷酸序列,如SEQ ID NO:1-SEQ ID NO:8所示。以及由具有SEQ ID NO:10-SEQ ID NO:17所示氨基酸序列的DNA序列编码的SARS-CoV病毒蛋白片段。通过使用初步获得的融合蛋白,通过将其片段附着于具有SEQ ID NO:9所示序列的N-末端GST-S-转移酶蛋白来分离所述片段。融合蛋白可用于制备诊断急性呼吸道病毒SARS-CoV的制剂。效果:用于诊断非典型肺炎的新型诊断剂; 2 cl
展开▼